These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 38402346)
1. Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis. Baccelli F; Gottardi F; Muratore E; Leardini D; Grasso AG; Gori D; Belotti T; Prete A; Masetti R Bone Marrow Transplant; 2024 Jun; 59(6):765-776. PubMed ID: 38402346 [TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre. Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis. Fan S; Huo WX; Yang Y; Shen MZ; Mo XD Front Immunol; 2022; 13():954268. PubMed ID: 35990629 [TBL] [Abstract][Full Text] [Related]
4. The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study. Yang W; Zhu G; Qin M; Li Z; Wang B; Yang J; Wang T Drug Des Devel Ther; 2021; 15():743-752. PubMed ID: 33654380 [TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients. Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598 [TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity. Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711 [TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature. Yan WL; Zhao FY; Gu ME; Liu N; Guo XP; Xu XJ Paediatr Drugs; 2023 Sep; 25(5):577-584. PubMed ID: 37284944 [TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib Pharmacokinetics and Pharmacodynamics in Children with Acute and Chronic Graft-versus-Host Disease. Cook E; Dong M; Chiang SCC; Luedeke D; Lake KE; Hoerth C; Deavy M; Setchell KDR; Zhao J; Punt N; Galletta T; Teusink-Cross A; Davies SM; Marsh RA; Mehta P; Khandelwal P Transplant Cell Ther; 2024 May; 30(5):528.e1-528.e12. PubMed ID: 38401793 [TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813 [TBL] [Abstract][Full Text] [Related]
10. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease. Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y Front Immunol; 2021; 12():673636. PubMed ID: 34276662 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies. Zhang MY; Zhao P; Zhang Y; Wang JS PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125 [TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib in patients with graft versus host disease (GvHD): findings from a compassionate use program. Pattipaka T; Sarp S; Nakhaei P; Güneş S Bone Marrow Transplant; 2024 May; 59(5):637-646. PubMed ID: 38361117 [TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis. Hui L; Qi L; Guoyu H; Xuliang S; Meiao T Expert Rev Hematol; 2020 May; 13(5):565-575. PubMed ID: 32178541 [No Abstract] [Full Text] [Related]
14. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study. Locatelli F; Antmen B; Kang HJ; Koh K; Takahashi Y; Kupesiz A; Dias Matos MGA; Chopra Y; Bhat S; Im HJ; Güngör T; Lu MY; Stefanelli T; Rosko C; St Pierre A; Burock K; Smith Y; Sinclair K; Diaz-de-Heredia C Lancet Haematol; 2024 Aug; 11(8):e580-e592. PubMed ID: 39002551 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis. Denk A; Mittermaier C; Weber D; Fante M; Güneş S; Edinger M; Herr W; Wolff D Ann Hematol; 2024 Sep; 103(9):3755-3764. PubMed ID: 38916742 [TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide. Zhao JY; Liu SN; Xu LP; Zhang XH; Wang Y; Chen YH; Liu KY; Huang XJ; Mo XD Ann Hematol; 2021 Jan; 100(1):169-180. PubMed ID: 33159239 [TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC. Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V; Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145 [TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience. Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510 [TBL] [Abstract][Full Text] [Related]